New drug combo takes on deadly brain tumor

NCT ID NCT05879250

Recruiting now Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This trial tests whether adding the drug WP1066 to standard radiation therapy can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. WP1066 targets a protein called STAT3 that helps tumors grow and hide from the immune system. The study will enroll 39 patients and measure how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WP1066 (a drug that blocks the STAT3 pathway to slow tumor growth and help the immune system attack cancer cells)
What this could lead to: If successful, this could lead to a new treatment option that extends survival for people with newly diagnosed glioblastoma.
What could go wrong: This is an early Phase II trial with only 39 participants, so results may not apply to all patients. The drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE MGMT-UNMETHYLATED GLIOBLASTOMA

Contacts and locations

Locations

Northwestern Medicine: Warrenville
ACTIVE_NOT_RECRUITING

Warrenville, Illinois, 60555, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.